How to appeal a Cigna autoimmune cytopenias (itp + aiha) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Cigna-specific note: Sold its Medicaid Advantage book to HCSC in 2023. Express Scripts (PBM) is Cigna-owned. Frequent class-action litigation around mental health parity.

What Cigna's policy requires for autoimmune cytopenias (itp + aiha)

Cited policy: Cigna Wayrilz (Rilzabrutinib) Chronic ITP PA

Persistent or chronic ITP. Insufficient response to >=1 prior ITP therapy. Adult >=18 yr per Aug 2025 label. Hematologist Rx. Dose 400 mg BID. Reauth 12 wk with platelet response and bleeding outcomes.

How Cigna denies autoimmune cytopenias (itp + aiha) — and how to counter it

Where Cigna pushes back: 1) Experimental / unproven; 2) Must fail multiple TPO-RAs and fostamatinib first; 3) Off-label or insufficient evidence.

Counter-arguments that hold up: Wayrilz (rilzabrutinib) FDA-approved Aug 29, 2025 — first covalent BTK inhibitor approved for ITP. Pivotal phase 3 LUNA-3 (NEJM 2024) — durable platelet response (>=50 x10^9/L on >=8 of 12 wk without rescue) 23% rilzabrutinib vs 0% placebo (p<0.0001), with QoL improvement on ITP-PAQ. Indication: persistent or chronic ITP with insufficient response to a previous treatment — explicitly NOT step-after-TPO-RA-and-fostamatinib. Mechanism (BTK inhibition reduces Fc-gamma signaling AND anti-platelet antibody production) distinct from TPO-RAs and SYK-i, supporting placement as parallel second-line option.

What Cigna typically denies for autoimmune cytopenias (itp + aiha)

Across Cigna's commercial and Medicare books, denials cluster around a small number of patterns. For autoimmune cytopenias (itp + aiha), expect:

• Mental health parity violations
• Step therapy
• Specialty drug prior auth
• OON balance billing disputes

Treatments most often denied in this category

These are the autoimmune cytopenias (itp + aiha) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Steroids (pred / dex)
• IVIG
• Anti-D (WinRho)
• Rituximab (off-label)
• Promacta (eltrombopag)
• Nplate (romiplostim)

How to submit the appeal to Cigna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Cigna cited in the denial.
3. File the appeal through Cigna's portal (members: https://my.cigna.com ; providers: https://cignaforhcp.cigna.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Cigna's prior-authorization criteria by drug: Cigna PA criteria on ApprovalHelp.